Progress and controversies: Treating obesity and insulin resistance in the context of hypertension

Journal of Clinical Hypertension

Volumn 11, Issue 1, 2009, Pages 36-41

  McGill, Janet B ^a,g   Haffner, Steven ^b   Rees, Tomas J ^c   Sowers, James R ^d   Tershakovec, Andrew M ^e   Weber, Michael ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c PAREXEL INTERNATIONAL   (United States)

^d University of Missouri   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f STATE UNIVERSITY OF NEW YORK   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FLUID RETENTION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE RATE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIFE STYLE; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 58149475241     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00065.x     Document Type: Review

References (40)

1. Antikainen RL, Moltchanov VA, Chukwuma C Sr, et al. Trends in the prevalence, awareness, treatment and control of hypertension: The WHO MONICA project. Eur J Cardiovasc Prev Rehabil. 2006;13:13-29.
2. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: Trends in prevalence, incidence, and control. Annu Rev Public Health. 2006;27:465-490.
3. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: What is the evidence? Clin Res Cardiol. 2007;96:247-257.
4. Geleijnse JM, Grobbee DE, Kok FJ. Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations. J Hum Hypertens. 2005;19(suppl 3):S1-S4.
5. Barba G, Russo O, Siani A, et al. Plasma leptin and blood pressure in men: Graded association independent of body mass and fat pattern. Obes Res. 2003;11:160-166.
6. Ruige JB, Dekker JM, Blum WF, et al. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study. Diabetes Care. 1999;22:1097-1104.
7. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
8. Monroe MB, Van Pelt RE, Schiller BC, et al. Relation of leptin and insulin to adiposity-associated elevations in sympathetic activity with age in humans. Int J Obes Relat Metab Disord. 2000;24:1183-1187.
9. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44:12-19.
10. Hausberg M, Hoffman RP, Somers VK, et al. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension. 1997;29:700-705.
11. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311-320.
12. Sarafidis PA, Bakris GL. The antinatriuretic effect of insulin: An unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007;27:44-54.
13. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597-H1602.
14. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol. 2007;580:31-37.
15. Lastra G, Manrique C, McFarlane SI, et al. Cardiometabolic syndrome and chronic kidney disease. Curr Diab Rep. 2006;6:207-212.
16. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463-473.
17. Zoccali C. Endothelial dysfunction and the kidney: Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol. 2006;17:S61-S63.
18. Ross WR, McGill JB. Epidemiology of obesity and chronic kidney disease. Adv Chronic Kidney Dis. 2006;13:325-335.
19. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 2003;26(suppl 1):S87-S88.
20. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-884.
21. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: A randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001;25:1713-1721.
22. Anderson JW, Schwartz SM, Hauptman J, et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: A 16week, double-blind, placebo-controlled trial. Ann Pharmacother. 2006;40:1717-1723.
23. Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens. 2008;26:357-367.
24. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: A meta-analysis of clinical studies. Diabetes Care. 2005;28:942-949.
25. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2007;31:138-146.
26. Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Arch Intern Med. 2000;160:494-500.
27. Fujimoto WY, Jablonski KA, Bray GA, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56:1680-1685.
28. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888-894.
29. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med. 2004;256:1-14.
30. Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2002;87:5503-5506.
31. Nilsson PM, Hedblad B, Donaldson J, et al. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press. 2007;16:95-100.
32. Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta. 2007;1771:999-1013.
33. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004;89:1140-1145.
34. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24:2047-2055.
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
36. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578-581.
37. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA. 2007;298:1189-1195.
38. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007;298:1180-1188.
39. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
40. Francischetti EA, Genelhu VA. Obesity-hypertension: An ongoing pandemic. Int J Clin Pract. 2007;61:269-280.